Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Muhammad Mujeeb-U-Rahman

Wireless Diagnostic Systems, Inc, USA

Title: Novel miniaturized, fully integrated, Wireless, Low-cost Glucose Sensing Platform

Biography

Biography: Muhammad Mujeeb-U-Rahman

Abstract

Diabetes is a significant health care issue which affects millions of people worldwide. Diabetes management at different stages requires glucose sensing followed by appropriate medical actions. Accurate and reliable sensing is an important component for the complete solution to disease management as well as to scientific studies required for better understanding of the disease and effect of different therapeutic factors for its prevention or treatment. To achieve the goal of low-cost, long term solution for accurate glucose sensing, we have been working on developing a novel, fully-integrated sensing technology which holds the key to solve the significant challenges inherent in current glucose sensing technologies. This system is based upon CMOS integrated electrochemical sensors with integrated control and autonomous wireless operation. A combination of extremely efficient circuit design, wireless operation (using RFID like technology) and Nanotechnology allows extreme miniaturization resulting in the smallest working platform to date. I will also present a smart external reader technology that can be used as a wearable device for continuous reading or used with smart phone for discrete readouts. In this talk, I will go through the motivation behind our smart design and the advantages it has over current devices, both commercial and research devices. I will explain the key design challenges and their effect on the overall system design. I will present the status of our work, including extensive in-vitro and preliminary in-vivo results. I will conclude with the plan to move forward with this technology and the clinical strategy to get this technology ready for human use.